Memantine

Uncompetitive, fast-off-rate NMDA channel blocker that uniquely intercepts pathological glutamate excitotoxicity while leaving normal synaptic transmission alone — the only NMDA antagonist with a real safety record in chronic daily human use (A-tier in moderate/severe Alzheimer's; B-tier in OCD, TBI, ADHD-adjunct). At biohacker doses (5-10 mg/day) the rationale is stimulant-tolerance modulation via NMDA-dependent dopamine sensitization pathways — mechanism is solid in animals, mostly anecdotal in humans. For Dylan: cheap generic Rx via telehealth, low side-effect profile, but the use-case (modafinil tolerance) is partially manufactured — modafinil tolerance is already minimal. OPTIONAL-WITH-CAVEATS, hold for if/when a classical stimulant enters the stack or if a sparring-derived TBI event creates acute need.

Memantine is a 1-amino-3,5-dimethyladamantane derivative — chemically an aminoadamantane cousin of amantadine — synthesized by Eli Lilly in 1968 (US patent 3,391,142, originally as a hypoglycemic agent that didn't pan out), shelved, then re-investigated by Merz (Frankfurt) starting 1982 when its central nervous system activity was discovered. Launched in Germany in 1989. Forest Laboratories licensed US rights from Merz; FDA approved Namenda for moderate-to-severe Alzheimer's October 17, 2003. Allergan acquired Forest in 2014, inheriting the franchise. Patent expired in 2015; generics now dominate.

Primary action — uncompetitive NMDA channel block with the "Goldilocks" kinetics that other NMDA antagonists lack:

The NMDA receptor is the brain's main calcium-permeable, voltage- and ligand-gated ion channel — the central node of synaptic plasticity (LTP, learning, memory) but also the gateway for glutamate excitotoxicity (calcium overload → mitochondrial collapse → neuronal death). Past attempts to drug NMDA were either useless (competitive antagonists like CGS-19755) or disastrous (ketamine, phencyclidine, MK-801 — high-affinity blockers that produce dissociation, psychosis, and Olney's-lesion-like neurotoxicity at therapeutic doses).

Memantine threads the needle. Three kinetic features distinguish it:

1. Low-to-moderate affinity (Ki ~0.5-1 µM at NR1/2A and NR1/2B receptors). Compare ketamine at ~0.5 µM but with much slower off-rate, and MK-801 at ~3 nM (~1000× higher affinity). At memantine's clinical brain concentrations (~1-10 µM) it occupies a useful fraction of NMDA channels but doesn't dominate them.

2. Strong voltage dependence. Memantine block deepens as the neuron depolarizes, similar to physiological Mg²⁺ block but with different IC₅₀ profile. At resting potential, physiological Mg²⁺ is the dominant blocker; at sustained depolarization (i.e., excitotoxicity), Mg²⁺ exits and memantine takes over. Magnesium imparts NMDA receptor subtype selectivity — physiological 1 mM extracellular Mg²⁺ decreases memantine inhibition of NR1/2A and NR1/2B receptors nearly 20-fold at near-resting voltage.

3. Fast off-rate ("fast unblocking kinetics"). This is the key differentiator from ketamine/MK-801. When a normal synaptic glutamate pulse arrives (millisecond timescale) and depolarizes the post-synaptic neuron, memantine pops out fast enough that physiological synaptic transmission proceeds. But during pathological tonic glutamate elevation (excitotoxicity, ischemia, chronic Aβ exposure — minutes to hours timescale), memantine accumulates in the open channel and blocks the calcium current. This is why memantine doesn't impair learning or LTP at therapeutic doses while still preventing excitotoxic neuronal death.

Extrasynaptic preference (Lipton group, Wu & Johnson 2010, J Neurosci 30:11246). At 1 µM, memantine blocks extrasynaptic NMDARs ~2× more effectively than synaptic NMDARs in hippocampal autapses, while MK-801 blocks both equally. Extrasynaptic NMDARs are NR2B-enriched, drive cell-death signaling (CREB shutoff, calpain activation), and are tonically activated by spillover glutamate; synaptic NMDARs (NR2A-enriched) drive pro-survival signaling. So memantine preferentially silences the bad NMDARs and spares the good ones — at least in vitro.

Sigma-1 receptor partial agonism. Memantine binds the sigma-1 receptor with Ki ~2.6 µM. Sigma-1 is a chaperone protein at the ER-mitochondria interface that modulates IP3 receptors, calcium handling, and dopamine/NMDA cross-talk. The affinity is low enough that sigma-1 contribution to therapeutic effects is contested — most reviewers consider it a minor pharmacological mechanism, not the dominant one.

Secondary off-target actions (clinically relevant or theoretically interesting):

• D2-high receptor partial agonism (Seeman et al. 2008, Synapse). Memantine binds D2-high (the high-affinity functional state of D2 receptors) with affinity equal to or slightly higher than its NMDA affinity. This is one mechanism for the modest dopamine release in PFC/striatum seen in microdialysis studies — and a likely contributor to the antiparkinsonian and pro-cognitive subjective effects.

• Nicotinic acetylcholine receptor antagonism (α7 and α4β2). Memantine non-competitively blocks neuronal nAChRs at sub-µM concentrations. Probably contributes to dizziness/cognitive blunting at higher doses; possibly relevant to mood effects.

• 5-HT3 receptor antagonism. Likely contributes to GI tolerability (anti-emetic angle) and possibly to mood effects (5-HT3 antagonists have anxiolytic signal).

• No CYP-driven metabolism. Memantine is ~48% excreted unchanged in urine; what is metabolized goes through hydroxylation/conjugation pathways, not CYPs. This is a huge advantage for stack-safety — no CYP induction or inhibition to worry about with modafinil, SSRIs, etc.

• Renal handling via OCT2 + MATE1. Active tubular secretion via organic cation transporter 2 (OCT2) on the basolateral side and multidrug and toxin extrusion 1 (MATE1) on the apical side, with pH-dependent reabsorption. Alkaline urine (pH >8) reduces clearance ~80% — relevant for high-dose sodium bicarbonate users (rare, but worth knowing).

Pharmacokinetics:

• Oral bioavailability ~100%. Food-independent (take with or without).
• Peak plasma concentration: 3-7 hours (immediate-release); 9-12 hours (Namenda XR extended-release).
• Terminal elimination half-life: 60-80 hours. This is unusually long — steady state takes ~2 weeks to reach. Translation: dose changes don't manifest fully for ~14 days, and missing a day barely matters.
• Linear PK over therapeutic dose range (5-20 mg).
• Renal clearance is dominant; severe renal impairment (CrCl 5-29 mL/min) requires dose halving to 5 mg BID max.